Skip to main content
. 2022 May;84(2):216–229. doi: 10.18999/nagjms.84.2.216

Fig. 4.

Fig. 4

Therapeutic targeting of super-enhancers in cancers

The discovery of JQ1 and other bromodomain inhibitors, as well as the preferential targeting of super-enhancers, has led to the development of several first- and second-generation bromodomain inhibitors. CDK7 (CDK12/CDK13) is also attracting attention as a target for cancer therapy; CDK7 inhibitors have been reported to be effective against various types of cancer.

BETi: bromodomain and extraterminal domain inhibitor